Recent national, European and international diabetes meetings have seen controversial discussions on the potential benefit and also on ethical aspects of immune intervention in patients with Type 1 diabetes or in persons with a high risk of developing the disease.
Therapeutic Immunology is a comprehensive review of the clinical application of the drugs, biologic agents, and procedures used to treat immunologic diseases. It is the only reference that provides current information on antibodies, cytokines, gene and cell therapies, vaccines, and other therapeutic approaches in the managament of immune system disorders. This book will show how immunology has come of age as a clinical discipline and is now able to provide treatment strategies for many previously incurable diseases.
This book is a compilation of the bench experience of leading experts from various research labs involved in the cutting edge area of research. The authors describe the use of stem cells both as part of the combinatorial therapeutic intervention approach and as tools (disease model) during drug development, highlighting the shift from a conventional symptomatic treatment strategy to addressing the root cause of the disease process. The book is a continuum of the previously published book entitled "Stem Cells: from Drug to Drug Discovery" which was published in 2017.
This important text will be the first devoted to a detailed analysis of immunotherapy as it ap-plies to Type I diabetes and the pathogenesis and therapy of other specific autoimmune diseases (including uveitis, multiple sclerosis, myasthenia gravis, Cogan's syndrome, Graves' ophthalmopathy, and gonadal disorders).
The vertebrate immune system defends the organism against invading pathogens while at the same time being self-tolerant to the body’s own constituents thus preserving its integrity. Multiple mechanisms work in concert to ensure self-tolerance. Apart from purging the T cell repertoire from auto-reactive T cells via negative selection in the thymus dominant tolerance exerted by regulatory T cells plays a major role in tolerance imposition and maintenance. Among the various regulatory/suppressive cells hitherto described, CD4+CD25+ regulatory T cells (Treg) and interleukin-10 producing T regulatory 1 (Tr1) cells have been studied in most detail and are the subject of most articles in this issue. Treg, also called "natural" regulatory T cells, will be traced from their intra-thymic origin to the site of their action in peripheral lymphoid organs and tissues. The repertoire of Treg is clearly biased towards recognition of self-antigens, thereby potentially preventing autoimmune diseases such as gastritis and oophoritis. Regulatory T cells, however also control infections, allergies and tolerance to transplanted tissues and this requires their induction in the periphery under conditions which are not yet fully understood. The concept of dominant tolerance, by far not novel, will offer new insights and hopefully tools for the successful treatment of autoimmune diseases, improved cancer immunotherapy and transplant survival. The fulfillment of these high expectations will, however, require their unambiguous identification and a better understanding of their mode of action.
This handbook is an invaluable resource for improving the management of diabetes. Chapters cover the fundamentals, including epidemiology, history and physical examination, and functional evaluations. Diabetes in children, adolescents, adults, and geriatrics are addressed. Differential diagnosis is emphasized, and evidence-based guidelines and patient-specific considerations aid the reader with injury evaluation and care. Notably, the book highlights the importance of understanding diabetic symptoms when determining the source of illnesses. In addition, the text presents the spectrum of treatment options for diabetes. The book is complete with appendices that explain the evidence-based approach used throughout and the science behind therapeutic modalities.
The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer
Beta cell replacement through transplantation remains the only treatment option for Type 1 diabetes enabling restoration of near-physiological glucose levels without significant hypoglycemia. Outlining the most recent advances and research breakthroughs, this practical guide and reference work explores the impact of islet cell transplantation and brings together leading multidisciplinary proponents critical to future success in the field. Edited by a surgeon and an endocrinologist at the forefront of the technology, this volume considers challenges associated with this procedure including lack of sufficient donor organs and the side effects of immunosuppressive therapy, as well as the potential benefits for current and future patients. Islet Transplantation and Beta Cell Replacement Therapy, after a brief historical overview, examines: the key role of endocrinologists in holistic assessment and selection of islet transplant recipients the factors underlying attrition of islet function over time and need for enhanced graft monitoring post transplantation future in vivo islet imaging setting up new clinical islet transplant programs by outlining potential models and pitfalls-including cost effectiveness and sustainable integrated approaches clinical outcomes and the future direction for islet transplantation, including alternative sources of beta cells, to meet future clinical needs through xenotransplantation, new insulin-producing cells from adult tissue, and stem cell banks
The book Immunopathogenesis and Immune-Based Therapy for Selected Autoimmune Disorders is a synthesis work that discusses two main aspects of autoimmunity: Immunopathogenesis and therapeutic approaches essentially based on the immunotherapies. This book deals with different topics on a number of autoimmune disorders, including type 1 diabetes, autoimmune cardiomyopathy, autoimmunity of gastrointestinal tract, systemic sclerosis, and myasthenia gravis. This book will be useful to clinicians, biologists, researchers, teachers, and students who are interested in immunology and immunopathology.